Wing Lam, PhD
Research & Publications
Biography
News
Research Summary
1. Development of YIV-906 (traditional Chinese medicine) as adjuvant for anti-cancer chemotherapy, in collaboration with Yiviva, Inc.
Extensive Research Description
• Currently developing YIV-906 for the treatment of inflammatory bowel disease (IBD).
• Demonstrated that YIV-906 increases the antitumor activity of Irinotecan, Sorafenib, and anti-PD1 activity in vivo, and promotes intestine recovery following Irinotecan/radiation treatment.
• Identified key mechanisms of action of YIV-906 for promoting tissue damage recovery and enhancing chemotherapy or immune therapy for treatment of cancer.
• Provided rationale for the initiation of a phase II clinical trial for the combination of Irinotecan and YIV-906 for the treatment of colon cancer, and the combination of Sorafenib and YIV-906 for the treatment of liver cancer.
Selected Publications
- A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC).Harding J, Abou-Alfa G, Shi Y, Whang-Peng J, Yuen M, Saif W, Tian A, Gu S, Lam W, Liu S, Cheng Y, Chu E, Yen Y. A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2020, 38: tps601-tps601. DOI: 10.1200/jco.2020.38.4_suppl.tps601.
- Abstract 2252: YIV-906 (PHY906) enhanced the anti-tumor activity of immune checkpoint blockade therapy (Anti-PD1) against liver cancer by changing the tumor micro-environment associated with M1 macrophages infiltrationLam W, Yang X, Jiang Z, han X, Guan F, Hu R, Xu C, Cai W, Cheng W, Liu S, Cai Y, Rattray N, Johnson C, Chen L, Cheng Y. Abstract 2252: YIV-906 (PHY906) enhanced the anti-tumor activity of immune checkpoint blockade therapy (Anti-PD1) against liver cancer by changing the tumor micro-environment associated with M1 macrophages infiltration. 2019, 2252-2252. DOI: 10.1158/1538-7445.sabcs18-2252.
- Abstract 2252: YIV-906 (PHY906) enhanced the anti-tumor activity of immune checkpoint blockade therapy (Anti-PD1) against liver cancer by changing the tumor micro-environment associated with M1 macrophages infiltrationLam W, Yang X, Jiang Z, han X, Guan F, Hu R, Xu C, Cai W, Cheng W, Liu S, Cai Y, Rattray N, Johnson C, Chen L, Cheng Y. Abstract 2252: YIV-906 (PHY906) enhanced the anti-tumor activity of immune checkpoint blockade therapy (Anti-PD1) against liver cancer by changing the tumor micro-environment associated with M1 macrophages infiltration. Cancer Research 2019, 79: 2252-2252. DOI: 10.1158/1538-7445.am2019-2252.
- Pilot trial of KD018 with neo-adjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer.Kann B, Johung K, Cheng Y, Lam W, Liu S, Decker R, Higgins S. Pilot trial of KD018 with neo-adjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Clinical Oncology 2017, 35: e15162-e15162. DOI: 10.1200/jco.2017.35.15_suppl.e15162.